Home / Combinations / KPV + Larazotide
CombinationRecoveryEmerging evidence
KPV + Larazotide
Gut Barrier & Anti-Inflammatory
KPV, a C-terminal tripeptide fragment of alpha-MSH, is researched for its MC1R-mediated anti-inflammatory action specifically in the gastrointestinal tract. Larazotide acetate (AT-1001) is investigated as a tight-junction regulator that reduces intestinal permeability. The combination is explored for supporting gut barrier integrity and managing mucosal inflammatory signaling.
Stack components
KPVCompound 01
LarazotideCompound 02
2
Compounds
2
Sources on file
4
Providers carry all
Mechanism
What each compound is researched for on its own. Nothing here describes an interaction between them.
Compound 01
KPV
Alpha-MSH C-terminal tripeptide researched for activating MC1R receptors in intestinal epithelial cells to reduce pro-inflammatory cytokine production locally in the GI tract.
Compound 02
Larazotide
Tight-junction regulatory peptide researched for reducing intestinal permeability by modulating zonulin-mediated tight junction dynamics in intestinal epithelial cells.
Composition
2 compounds · 1 research area
Stated as recorded. This page describes each compound separately and makes no claim that they act together.
Safety notes
Larazotide has been studied in human clinical trials for celiac disease and intestinal permeability with a well-documented safety profile. KPV research is primarily preclinical and early-phase. Neither peptide is associated with systemic immunosuppression at research doses.
Author-written. Not derived from any compound field, and not covered by the profile-integrity audit that gates the peptide pages.
Research references2 sources
Moderate
The tripeptide KPV suppresses intestinal inflammation via melanocortin-1 receptor
Biochem Pharmacol 2006
PeptideBase notePer-component source only — no combination study exists
no identifier on file
Strong
Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet
Gastroenterology 2015
PeptideBase noteLarazotide human clinical trial — no combination study exists
Related combinations3 share an area
Anti-Aging · Recovery
Thymalin + Epithalon: Immune-Longevity Protocol
Thymalin+Epithalon
Muscle Growth · Fat Loss · Recovery
CJC-1295 + Ipamorelin + GHRP-6: GH Secretagogue Max
CJC-1295+Ipamorelin+GHRP-6
Muscle Growth · Fat Loss · Recovery · Anti-Aging
CJC-1295 + Ipamorelin: GH Optimization
CJC-1295+Ipamorelin
Educational use only
PeptideBase documents what compounds are researched together and what evidence exists for each one separately. It does not provide medical advice, diagnosis, treatment, prescribing guidance or dosing instructions. Last reviewed 23 Apr 2026.
PeptideBase documents what compounds are researched together and what evidence exists for each one separately. It does not provide medical advice, diagnosis, treatment, prescribing guidance or dosing instructions. Last reviewed 23 Apr 2026.